Genome&Company Selected for National New Drug Development Project with Immune Checkpoint Inhibitor 'GENA-104'
[Asia Economy Reporter Lee Gwan-joo] Genome&Company announced on the 7th that its immuno-oncology drug 'GENA-104' has been selected as a non-clinical development project under the National New Drug Development Project's 'New Drug R&D Ecosystem Establishment Research.'
Through this project selection, Genome&Company will receive approximately 1.5 billion KRW in research and development funding for GENA-104 over two years.
GENA-104 is an immune checkpoint inhibitor candidate that suppresses the newly discovered target 'CNTN-4,' identified through Genome&Company's new drug development platform 'GNOCLETM.' Existing approved immune checkpoint inhibitors target 'PD-1' or 'PD-L1,' but they have the limitation of showing efficacy in only about 20% of cancer patients. To overcome this, various studies are underway, and Genome&Company is developing an immune checkpoint inhibitor based on a new target.
The newly discovered target CNTN-4, first identified by Genome&Company, is expressed significantly more than PD-L1 in many cancer types, raising expectations that GENA-104 will become a novel mechanism immune checkpoint inhibitor that can meet the unmet needs of cancer patients unresponsive to existing immune checkpoint inhibitors.
In preclinical studies, GENA-104 was confirmed to inhibit CNTN-4, activate immune cells (T cells), and effectively induce cancer cell death. It is currently in the non-clinical stage, with plans to apply for a Phase 1 IND in 2023.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Cha Mi-young, head of Genome&Company's New Drug Research Institute, said, “With the selection of this National New Drug Development Project, we will receive research funding for non-clinical toxicity testing and clinical sample production, laying the foundation for successful clinical progress. We will accelerate development to launch innovative new drugs that can lead the global immuno-oncology market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
